Result of AGM

LungLife AI, INC

05 June 2024

 

LungLife AI, Inc.

("LungLife" or the "Company")

Result of Annual General Meeting

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at its Annual General Meeting, held at earlier today, all 10 resolutions put to members were passed on a poll.

Full details of the voting will be available shortly on the Company website here: https://lunglifeai.com/investors/financial-information-documents-presentations/

For further information please contact:

LungLife AI, Inc.	www.lunglifeai.com
Paul Pagano, CEO	Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser & Broker)	Tel: [phone]
Virginia Bull / Cameron MacRitchie / Lydia Zychowska
Goodbody (Joint Broker)	Tel: [phone]
Tom Nicholson / Cameron Duncan
Walbrook PR Limited	Tel: [phone] or [e-mail]
Alice Woodings / Phillip Marriage	Mob: [phone]

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

Our Purpose is to be a driving force in the early detection to lung cancer.  Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

 

END